Structured Treatment Interruption for HIV Patients With Virologic Failure

This study has been completed.
Sponsor:
Collaborators:
Canadian Institutes of Health Research (CIHR)
CIHR Canadian HIV Trials Network
Information provided by:
University Health Network, Toronto
ClinicalTrials.gov Identifier:
NCT00188851
First received: September 12, 2005
Last updated: NA
Last verified: September 2005
History: No changes posted
  Purpose

The purpose of this study is to assess the virologic impact of switching treatment-experienced HIV-infected patients with virologic failure to a salvage regimen with or without a 12 week STI prior to the switch.

Hypothesis: A STI prior to starting a salvage regimen will result in an improved virologic response.


Condition Intervention
HIV
Drug: therapeutic management strategy

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Prospective Randomized Trial of Structured Treatment Interruption(STI) Followed by Initiation of a New Antiretroviral Regimen(ARV) Versus Immediate Switching to a New ARV in HIV-Infected Patients Experiencing Virologic Failure on HAART

Resource links provided by NLM:


Further study details as provided by University Health Network, Toronto:

Primary Outcome Measures:
  • To prospectively determine the virologic impact of switching treatment-experienced HIV-infected patients with virologic failure to a salvage regimen with or without a 12 week STI prior to the switch.

Secondary Outcome Measures:
  • 1. To prospectively determine differences in other virologic parameters through follow up between patients being switched to a salvage regimen with or without a STI.
  • 2. To prospectively determine differences in change in CD4 count through follow up and at 24, 48 and 60 weeks following randomization between patients being switched to a salvage regimen with or without a STI.
  • 3. To prospectively determine differences in the development or reactivation of opportunistic infections and survival between patients being switched to a salvage regimen with or without a STI at 60 weeks following randomization
  • 4. To determine the proportion of virus of patients being treated with a STI that converts to wild-type and how that relates to the virologic response (% of patients with undetectable viral load sustained for 3 months).
  • 5. To determine the impact of the STI on quality of life measures.
  • 6. To determine the genotypic resistance pattern of virus from patients who fail treatment after suppression to <50 copies/mL on the salvage regimen and to compare results in those who do and do not receive an STI.

Estimated Enrollment: 196
Study Start Date: January 2001
Estimated Study Completion Date: November 2005
Detailed Description:

To prospectively determine the virologic impact of switching treatment-experienced HIV-infected patients with virologic failure to a salvage regimen with or without a 12 week STI prior to the switch.

Hypothesis: By withdrawing ARV drug pressure, resistant HIV virus will revert to wild-type. In treatment-experienced HIV patients who experience virologic failure, a STI prior to starting a salvage regimen will result in an improved virologic response and more prolonged vral suppression compared to immediate switching to a new regime.

Interventions:

Immediate Switch to Salvage Therapy: Patients randomized to the control arm will be switched immediately to a salvage regimen using the information from the treatment history and genotype results.

Structured Treatment Interruption: Patients randomized to the STI arm will have their present regimen stopped for 12 weeks and will have a genotype repeated in the 12th week. A salvage regimen will be started at week 12 using the information from the treatment history and baseline genotype results.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Age > 18 years.
  • On therapy with a triple ARV that includes a protease inhibitor and/or non-nucleoside reverse transcriptase inhibitor for the past 3 months with no changes in any agent of the combination in the past 14 days.
  • Virologic failure while on the combination as defined by a plasma HIV RNA > 1000 copies/mL measured on 2 occasions at least 4 weeks apart.
  • HIV RNA <500,000 copies/mL.
  • CD4 cell count must be > 50/mm3
  • Patients must not have a present history of opportunistic infections or acute illness requiring treatment within the preceding 30 days.
  • The patient has at least two new ARV available based on history, and at least two of these new agents will be included in the new salvage regimen.

Exclusion Criteria:

  • Active substance abuse which would interfere with the patient's ability to participate in this trial, or declared non-compliance.
  • Pregnancy or breast feeding.
  • Patients with any of the following abnormal laboratory test results at screening:· Hemoglobin<80 g/L, neutrophil count<750 cells/mL, Platelet<20,000 /mL· AST or ALT > 5X Upper Limit of Normal (ULN)· Creatinine > 250 umol/L
  • End stage organ disease
  • Patient with malignancy receiving systemic chemotherapy
  • Patient has need for immune modulators (interleukin, interferon, GMCSF etc) or prednisone. This excludes a short course of inhaled or oral steroids for asthma exacerbation)
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00188851

Sponsors and Collaborators
University Health Network, Toronto
Canadian Institutes of Health Research (CIHR)
CIHR Canadian HIV Trials Network
Investigators
Study Chair: Mona Loutfy, MD University Health Network, Toronto, On
Study Director: Joel Singer, MD Canadian Trials Network, Vancouver, B.C.
Study Director: Janet Raboud, Dr. Univeristy Health Network, Toronto, On
Study Director: Stephen Shafran, MD University of Alberta, Edmonton, Alberta
Study Director: Bill Cameron, MD Ottawa Hospital, Ottawa, On
Study Director: Sylvie Trottier, MD Clinique Medicale L'Actuel, Montreal, Quebec
Study Director: Richard Harrigan, MD B.C. Centre of Excellence, Vancouver, B.C.
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00188851     History of Changes
Other Study ID Numbers: CIHR82716
Study First Received: September 12, 2005
Last Updated: September 12, 2005
Health Authority: Canada: Health Canada

Keywords provided by University Health Network, Toronto:
HIV
salvage regimen
virologic failure
treatment interruption
ARV experienced

ClinicalTrials.gov processed this record on August 19, 2014